The American Society of Nephrology (ASN) Kidney Week 2023 will take place in Philadelphia, Pennsylvania, from November 2-5, as experts from across the globe gather to discuss the latest innovations in renal care and current issues facing the field.
Thousands of clinicians and investigators will gather this week for the American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, Pennsylvania. The meeting will be returning to Philadelphia for the first time since 2014 and, notably, will feature new data regarding the role artificial intelligence (AI) and digital health in the field of nephrology.
The early agenda for ASN 2023 includes recurring programs bringing updates on maintenance dialysis, kidney transplantation, renal pathology, and glomerular disease; however, this year’s congregation will also introduce new programs presenting on the emerging field of nephrocardiology, advancements in multi-omics, as well as genetic testing in clinical nephrology.
Several posters will showcase new technological innovations regarding the use of AI in renal care. Presented data will touch on AI’s capacity to predict outcomes in, for example, cases of acute kidney injury (AKI), interdialytic hypotension, as well as dialysis and the associated hurdles with accessing adequate care. Furthermore, the potential efficacy of ChatGPT as a resource in patient care will be showcased in posters such as “Application of Large Language Models Such as ChatGPT to Support Nutritional Recommendations for Dialysis Patients.” Multiple poster sessions modeling the benefits of machine learning–based approaches will also be included.
Among the educational opportunities highlighting technological advancements, this year’s meeting also emphasizes the disparities and shortcomings clinicians, researchers, and patients face in the field of nephrology.
These issues are reflected in sessions such as “Health Care Equity in Education, Clinical Care, and Community Engagement,” which will offer valuable perspectives on antiracism, the importance of cohort diversity in clinical trials, and the power of engaging with patients and their communities. Other presentations in line with these educational aims include “Social Determinants of BP and CVD in Patients with CKD” and “We Are Never Over the Rainbow: Nephrology Care for the LGBTQ+ Community,” which will evaluate the demographic factors that can influence outcomes or care approaches in certain patient populations.
The agenda will also feature a plethora of sessions concerning diabetic kidney disease, chronic kidney disease, nephrology in geriatric and pediatric populations, onconephrology, advances in bone and mineral metabolism, pharmacology, and discoveries in renal pathology.
The ASN’s goals for this year’s Kidney Week are solely learning based. As the presentations inform physicians, researchers, and other medical professionals on the newest discoveries in nephrology, they hope attendees can walk away from this meeting fully equipped to expand on this data and form new research questions to guide clinical practice and science moving forward.
Study Highlights Key RA-ILD Risk Factors, Urges Early Screening
November 20th 2024This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.
Read More
Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed
November 20th 2024Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.
Read More
Building Trust, Breaking Barriers: Health Care Leaders Tackle Primary Care Challenges
August 8th 2024On this episode of Managed Care Cast, we're talking with the chief medical officers of CVS Health and Aetna, as well as CVS Health's chief health equity officer, about primary and preventive care engagement, the impact of telehealth, and the role of trust in patient-provider relationships.
Listen
New PsA Data Highlight Long-Term Benefits of Bimekizumab
November 19th 2024A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).
Read More